| Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ... New England journal of medicine 384 (5), 403-416, 2021 | 10448 | 2021 |
| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 984 | 2022 |
| Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase HM El Sahly, LR Baden, B Essink, S Doblecki-Lewis, JM Martin, ... New England Journal of Medicine 385 (19), 1774-1785, 2021 | 544 | 2021 |
| Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants A Pegu, SE O’Connell, SD Schmidt, S O’Dell, CA Talana, L Lai, J Albert, ... Science 373 (6561), 1372-1377, 2021 | 543 | 2021 |
| SARS-CoV-2 variant B. 1.1. 7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines X Shen, H Tang, C McDanal, K Wagh, W Fischer, J Theiler, H Yoon, D Li, ... Cell host & microbe 29 (4), 529-539. e3, 2021 | 422 | 2021 |
| Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents K Ali, G Berman, H Zhou, W Deng, V Faughnan, M Coronado-Voges, ... New England Journal of Medicine 385 (24), 2241-2251, 2021 | 408 | 2021 |
| SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination R Pajon, NA Doria-Rose, X Shen, SD Schmidt, S O’Dell, C McDanal, ... New England Journal of Medicine 386 (11), 1088-1091, 2022 | 368 | 2022 |
| Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis A Choi, M Koch, K Wu, L Chu, LZ Ma, A Hill, N Nunna, W Huang, ... Nature medicine 27 (11), 2025-2031, 2021 | 364 | 2021 |
| A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine L Chu, R McPhee, W Huang, H Bennett, R Pajon, B Nestorova, B Leav, ... Vaccine 39 (20), 2791-2799, 2021 | 251 | 2021 |
| Neutralization of SARS-CoV-2 variants B. 1.429 and B. 1.351 X Shen, H Tang, R Pajon, G Smith, GM Glenn, W Shi, B Korber, ... New England Journal of Medicine 384 (24), 2352-2354, 2021 | 245 | 2021 |
| Bexsero: a multicomponent vaccine for prevention of meningococcal disease AR Gorringe, R Pajón Human vaccines & immunotherapeutics 8 (2), 174-183, 2012 | 147 | 2012 |
| Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age CB Creech, E Anderson, V Berthaud, I Yildirim, AM Atz, I Melendez Baez, ... New England Journal of Medicine 386 (21), 2011-2023, 2022 | 145 | 2022 |
| Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants A Choi, M Koch, K Wu, G Dixon, J Oestreicher, H Legault, ... Journal of virology 95 (23), 10.1128/jvi. 01313-21, 2021 | 121 | 2021 |
| Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial S Chalkias, F Eder, B Essink, S Khetan, B Nestorova, J Feng, X Chen, ... Nature medicine 28 (11), 2388-2397, 2022 | 117 | 2022 |
| Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates R Pajon, PT Beernink, LH Harrison, DM Granoff Vaccine 28 (9), 2122-2129, 2010 | 90 | 2010 |
| Outer membrane vesicles of the VA‐MENGOC‐BC® vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two‐dimensional … L Uli, L Castellanos‐Serra, L Betancourt, F Domínguez, R Barberá, ... Proteomics 6 (11), 3389-3399, 2006 | 89 | 2006 |
| Mapping SARS-CoV-2 antigenic relationships and serological responses SH Wilks, B Mühlemann, X Shen, S Türeli, EB LeGresley, A Netzl, ... Science 382 (6666), eadj0070, 2023 | 87 | 2023 |
| Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization NA Doria-Rose, X Shen, SD Schmidt, S O’Dell, C McDanal, W Feng, ... MedRxiv, 2021 | 87 | 2021 |
| A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus A August, HZ Attarwala, S Himansu, S Kalidindi, S Lu, R Pajon, S Han, ... Nature medicine 27 (12), 2224-2233, 2021 | 82 | 2021 |
| Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster K Wu, A Choi, M Koch, LZ Ma, A Hill, N Nunna, W Huang, J Oestreicher, ... MedRxiv, 2021.05. 05.21256716, 2021 | 81 | 2021 |
David C Montefiori, Ph.D.Duke University Medical Center在 duke.edu 的电子邮件经过验证
